Press Release
PhaseBio Pharmaceuticals to Host Virtual Investor and Analyst Day on March 15, 2021
Guest speakers Include
Presentations from PhaseBio Leadership Team
Presenters Include:
-
Deepak Bhatt , MD, MPH, FACC, FAHA, FSCAI, FESC, Executive Director of Interventional Cardiovascular Programs, Brigham and Women's Hospital Heart & Vascular Center and Professor of Medicine atHarvard Medical School -
John Fanikos , RPh, MBA, Director of Pharmacy Business and Financial Services, Brigham and Women’s Hospital -
Jonathan Mow , Chief Executive Officer, PhaseBio -
John Lee , MD, Chief Medical Officer, PhaseBio -
Susan Arnold , PhD, Vice President, Preclinical & CMC, PhaseBio -
Lauren Richardson , Global Head, Regulatory Affairs and Quality Assurance, PhaseBio -
Michael York , Vice President,Corporate Development & Commercial Strategy , PhaseBio
The presentations will be followed by Q&A with the PhaseBio management team and guest speakers.
Video Webcast and Replay
A live video webcast will be streamed along with accompanying slides. Interested parties may RSVP to join the virtual event through the following registration link: http://wsw.com/webcast/cc/phas
A webcast replay of the event and slides will be available for 30 days on the Events & Presentations page of the “Investors” section of the company’s website at www.phasebio.com.
About Bentracimab (PB2452)
Bentracimab is a novel, recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations. In a Phase 1 clinical trial, bentracimab demonstrated the potential to bring life-saving therapeutic benefit through immediate and sustained reversal of ticagrelor’s antiplatelet activity, mitigating concerns regarding bleeding risks associated with the use of this antiplatelet drug. The Phase 1 clinical trial of bentracimab in healthy volunteers was published in the
About PhaseBio
PhaseBio is located in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements.
Forward-looking statements include statements concerning or implying the conduct or timing of our clinical trials and our research, development and regulatory plans for our product candidates, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224006077/en/
Investor Contact:
Chief Financial Officer
(610) 981-6506
john.sharp@phasebio.com
Media Contact:
will.zasadny@canalecomm.com
(619) 961-8848
Source: